

Maternal Serum Disintegrin and Metalloprotease Protein-12 (ADAM 12) In First Trimester as a Marker of Early Adverse Pregnancy Outcomes

*Wasanwajdi, Ficog, Nada Saed Abbas** Mbchb, Fibgo, Ishraq M.
Kadhim* Mbchb., Cabgo, Zeena Abdulalahyaseen**
, Mbchb, Muhammed Waheebal, Obaidy* Faccp
* Dept Of Obstetrics & Gynecology, College Of Medicine, University Of Baghdad
** Medical City Complex, Baghdad Teaching Hospital.

Abstract:

Background: ADAM 12, a multidomain polypeptide, is a placental protein, that is involved in growth and differentiation of placenta and fetus secreted from the invasive extra villous trophoblasts and trophoblasts in distal anchoring columns in early gestation placental villi. ADAM12, existing as two distinct splice variants (ADAM12L and ADAM12S), promoting cell migration and invasion of the placenta, poor invasion of the placenta leads to adverse first trimester outcomes.

Objectives: To determine whether the maternal serum concentration of A disintegrin and metalloprotease protein 12 (ADAM12) in first trimester can be considered as an indicator of first-trimester spontaneous abortions, missed abortions, ectopic pregnancies and hydatidiform moles.

Patients and methods: This case control study was carried out during period from the 1st of March to the 30th of November 2016 at Baghdad Teaching Hospital in Obstetrics and Gynecology department. Two hundred pregnant women were enrolled in this study, one hundred of them were control group and the remainder (n=100) are divided to complete abortion (n=25), missed abortion (n=25), ectopic pregnancy (n=25), molar pregnancy (n=25). The maternal serum concentration of ADAMs were measured between (5-9th wks) of gestation using enzyme-linked immunosorbent assay (ELISA).

Results: The level of ADAM12 increased with gestational age in the control group. The mean level of ADAM12 in spontaneous abortion 10.3 ng/ml, in ectopic pregnancy 4.9 ng/ml and in hydatidiform mole 6.4 ng/ml groups which were higher than that in the control, while the mean level of ADAM12 in the missed abortion group 1.6 ng/ml which was not significant from the control (2.8 ng/ml). Logistic regression analysis demonstrated that ADAM level was significantly predicting ectopic pregnancy, molar pregnancy and spontaneous abortion with OR (0.3), OR (0.4), and OR (1.8) respectively.

Conclusions: The level of the maternal serum ADAM-12 in early pregnancy can be considered as an indicator of early adverse pregnancy outcome.

Keywords: ADAM12, ectopic pregnancy, molar pregnancy, spontaneous abortion.

Date of Submission: 12-10-2017

Date of acceptance: 30-09-2017

I. Introduction

Pregnancy is the term used to describe the period in which a woman carries a fetus usually inside of the uterus^(1,2). Fertilization describes the process by which a ("zygote") is formed, if fertilization does occur, the zygote divides and differentiates into a "pre-embryo" while being carried down the fallopian tube toward the uterus⁽³⁾. Cell division of the zygote, results in blastocyst⁽⁴⁾. The period from 3 – 8 weeks in human is called the *Embryonic Stage*: it is the period in which cell division and cellular differentiation of the zygote occur^(5,6). The period from the beginning of the 9th week to birth is known as the *fetal period*. It is characterized by maturation of tissues and organs and at this stage the risk of miscarriage decreases sharply^(7,8). Any pregnancy in the first trimester may end either in: Healthy viable fetus, Miscarriage, Ectopic pregnancy (the implantation is in the wrong place) and Molar pregnancy (a premalignant tumor that develops in the uterus)^(9,10).

A Disintegrin and A Metalloprotease protein 12 (ADAM12) is a cellular Trans membrane polypeptide chain composed of unique multiple domains; the signal peptide, the pro domain, the metalloprotease, the disintegrin, the cysteine-rich, and the EGF (epidermal growth factor-like domains), as well as the trans membrane segment and the cytoplasmic tail^(11,12). They play pivotal roles in the proteolytic degradation of the extracellular matrix for cell invasion⁽¹³⁾, cell adhesion, cell fusion signaling^(14,15), fertilization and

ectodomains shedding⁽¹⁶⁾. The multidomain structure allows the ADAM family of proteins to perform such various physiological tasks⁽¹⁷⁾. Human **ADAM12** exists in 2 variants by alternative splitting of ADAM 12 gene which locates in human chromosome 10q26.2.^(18,19) ADAM 12 level increase in pregnancy, where as in non pregnant women, its level is undetected only in some diseases or cancers, gestational age is likely to be a key factor in ADAM 12 levels, it rises from 5 weeks of gestation^(20,21), this increase in serum levels of ADAM12 with gestation presumably reflects its increased production, as well as its improved transport due to the establishment of the uteroplacental circulation. While in non-pregnant women its level about zero^(22,23). The source of ADAM 12S is suggested to be the placenta^(24,25).

ADAM 12 have many roles in pregnancy such as possesses gelatinase activity which cleaves extracellular matrix proteins, such as gelatin, and help extra villous trophoblasts to invade endometrium and myometrium during pregnancy. also participates in cell signaling and increases insulin growth factor by the action of its metalloprotease domain on the insulin growth factor binding protein 3 and 5 (IGFBP 3 & 5).^(15,16,17,18,22)

Aim Of This Study: To determine whether the concentration of A disintegrin & metalloprotease protein 12S (ADAM 12) measure in serum during first trimester could be considered as an indicator of early adverse pregnancy outcome.

II. Patients And Methods

This study is a case-control study, carried out during the period from the 1st of March 2016 to the 30th of November 2016, at Baghdad teaching hospital/medical city complex in Obstetrics and Gynecology department.

Two hundred pregnant women with gestational age 5- 9 +6weeks were enrolled in this study and they were divided into the following groups:

Group A: 100 pregnant women with viable intrauterine pregnancy between (5-9⁺⁶ weeks) as a control group.

Group B: 100 pregnant women presented at the outpatient department with either abdominal pain &/or vaginal bleeding and were admitted as inpatient then grouped into groups according to their diagnosis and to the specific ultrasound criteria of each of first trimester complications as follows:

1. 25 women with complete spontaneous abortion. The report of ultrasound must be: Empty uterus with endometrial thickness at least 16 mm or small retained pieces of conception with previous ultrasound report of healthy viable intrauterine pregnancy.
2. 25 women with ectopic pregnancy.
3. 25 women with missed abortion
4. 25 women with molar pregnancy.

Full history taken from all pregnant women (control & cases) including demographic details (name, age and occupation), history regarding her recent pregnancy (gestational age was calculated depending on her last menstrual period and by ultra-sonographic measurement of the crown-rump length).

Exclusion criteria:

pregnant women above 40 years old, Patient with twin pregnancies or higher order pregnancies, Patient with medical diseases (rheumatoid arthritis, asthma, cardiac hypertrophy), Patient with a known or suspicious cancers, Any patient with history of previous pre-eclampsia, or strong history of Down syndrome or Intrauterine growth restriction. For confirmation of the diagnosis, in patient with incomplete abortion, missed abortion, suspected molar pregnancies, placental tissue was sent to histopathology, patient with ectopic pregnancies specimens of salpingectomy was sent for histopathology. After confirmation by histopathology the patients were included in the study. Five milliliters of maternal blood aspirated peripherally from the ante cubital vein from the all subjects included in the study, and left to clot for 30 minutes at room temperature before centrifugation for 15 minute, then the serum is collected and stored at less or equal to -20 centigrade Celsius until assayed. Sera were assayed using the ADAM12 Quantikine ELISA kit (R&D systems)

- Sensitivity of the test: the minimum detectable dose of human ADAM 12 ranged from **0.016-0.076 ng/ml**. The mean MDD was **0.030 ng/ml**.
- Normal range of ADAM 12 from sera of apparently healthy non pregnant volunteers = **zero to 0.473 ng/L**.

III. Statistical Analysis

All patients' data entered using computerized statistical software; Statistical Package for Social Sciences (SPSS) version 21 was used. Descriptive statistics presented as (mean \pm standard deviation) and frequencies as percentages. Kolmogorov Smirnov analysis verified the normality of the data set. Multiple contingency tables conducted and appropriate statistical tests performed, fisher's exact test used for categorical variables and One way ANOVA analysis was used to compare between more than two means. ROC curve was

used to clarify validity tests. In all statistical analysis, level of significance (p value) set at ≤ 0.05 and the result presented as tables.

IV. Results

A total of two hundred pregnant women in first trimester were included in this study, one hundred of them considered as (control group) and remaining one hundred divided to four groups (ectopic, missed, molar and spontaneous). All these pregnant women divided to three groups according to the age.

Table 1: showed no significant difference in maternal age between control and study groups ($p=0.1$), but there was a significant association between women with molar pregnancy and increased gestational age ($p=0.001$).

Table 1: Distribution Of Age And Gestational Age According To Study Groups.

Variable	Control		Ectopic		Molar		Missed		Spontaneous		P
	No.	%	No.	%	No.	%	No.	%	No.	%	
Age											0.1*
<20 years	26	6.0	0	-	4	16.0	2	8.0	0	-	
20-29 years	46	66.0	20	80.0	15	60.0	17	68.0	13	52.0	
30-40 years	28	28.0	5	20.0	6	24.0	6	24.0	12	48.0	
Mean age	27.3±3.2		27.4±2.6		28.1±1.7		27.1±3.3		26.8±1.1		0.001*
Gestational age											
5 th week	7	7.0	2	8.0	2	8.0	0	-	0	-	
6 th week	20	20.0	5	20.0	0	-	4	16.0	5	20.0	
7 th week	43	43.0	9	36.0	2	8.0	8	32.0	2	8.0	
8 th week	16	16.0	6	24.0	11	44.0	11	44.0	11	44.0	
9 th week	11	11.0	2	8.0	0	-	1	4.0	7	28.0	
10 th week	3	3.0	1	4.0	10	40.0	1	4.0	0	-	
Mean gestational age	6		6		7		7		7		

There was a highly significant association between higher ADAM mean levels and increased gestational age of the control pregnant women. Table 2.

Table 2: Distribution of ADAM mean according to gestational age of control pregnant women.

GA groups	ADAM Mean±SD
5 th week	2.3±1
6 th week	2.3±2.2
7 th week	2.6±2.1
8 th week	5±3.7
9 th week	7.8±4.1
10 th week	8.2±4.5
P value*	<0.001

Most of healthy control pregnant women had normal obstetrical history and only 7% of them had abnormal obstetrical history as shown in Table 3.

Table 3: Distribution of pregnant control women characteristics.

Variable	No.	%
Obstetrical history of controls		
Normal	93	93.0
Abnormal	7	7.0
Total	100	100.0

Higher ADAM mean level was significantly associated with pregnant women with spontaneous abortion ($p<0.001$). Post Hoc test showed a significant higher mean of ADAM of women with ectopic pregnancy in comparison to controls ($p<0.001$), in same direction ADAM mean was significantly higher among women with molar pregnancy and spontaneous abortion in comparison to controls ($p<0.001$). No significant difference in ADAM mean between women with missed abortion and controls ($p=0.9$). Table 4.

Table 4: Distribution of ADAM meanin the study groups.

Groups	ADAM	Post Hoc test (P value)	
	Mean±SD		
Control	2.8±2.2		
Ectopic pregnancy	4.9±3.1	Ectopic & control	<0.001
Molar pregnancy	6.4±3.2	Molar & control	<0.001
Missed abortion	1.6±0.9	Missed & control	0.9
Spontaneous abortion	10.3±2.2	Spontaneous & control	<0.001
ANOVA (P value)	<0.001		

ADAM12 level of pregnant women was significantly predicting ectopic pregnancy with OR (0.3), ADAM level of pregnant women was significantly predicting molar pregnancy with OR (0.4) and ADAM level of pregnant women was significantly predicting spontaneous abortion with OR (1.8) as shown in table 5 .

Table 5: Multiple logistic regression analysis of ADAM 12 level prediction of pregnancy outcome at first trimester.

Variable	β	OR	P
Ectopic pregnancy	-1.1	0.3	<0.001
Molar pregnancy	-0.7	0.4	<0.001
Missed abortion	-0.3	0.2	0.1
Spontaneous abortion	-2.3	1.8	<0.001

V. Discussion

ADAM12 is produced by the placenta and is present in the serum of gravid women, but not in the serum of non-pregnant women, but there is no unified level of ADAM 12 S specific to each gestational week⁽⁷⁾. The results of the **current study**, that the maternal serum ADAM12 concentration in normal pregnancies increased with gestational age between 5–9⁺⁶wks gestation from 2.6 ng/ml to 8.2 ng/ml, these results agree with Sahraravand et al study⁽²⁶⁾ where ADAM 12 increase continuously from week 5 (2.1 microgram/L) to a value of (553.82.1 microgram/L) at 11 week and Yang, Jiexia, et al study⁽²⁷⁾ where ADAM 12 at 5 weeks is 10 microgram/L to 175 microgram/L at 9^{+6 days} weeks .

Regarding ectopic pregnancy: thisstudy showed that the mean maternal serum level of ADAM12 in ectopic pregnancy is 4.9±3.1 ng/ml which is significantly higher than the control with P value of < 0.001. This disagree with Yang, Jiexia, et al.⁽²⁷⁾, in which the study involve **56** of ectopic pregnancies studied and compared with normal Intrauterine pregnancies, the MOM was 0.460, which is lower than the level in normalintrauterine pregnancies, also disagree with Rauch et al. study⁽²⁸⁾ which found a statistically significant decrease in a disintegrin and metalloprotease protein-12 (ADAM-12) in the sera of patients with Ectopic pregnancy (median 2.5 ng/ml), when compared to women with viable intrauterine pregnancy (median 18.6 ng/ml) , and disagree with Horne et al . study⁽²⁹⁾ which considered ADAM 12 levels had limited value as a diagnostic marker for ectopic pregnancy . the study involved 120 patients with ectopic pregnancy, serum ADAM 12 concentration were increased with histologically – confirmed ectopic pregnancy (median 442 pg/ ml) compared to women with viable intrauterine pregnancies (median 256 pg/ml).This disagreement is due to small sample of study group (ectopic group) .

Regardingspontaneousabortion:In the current study, the mean of ADAM12 in complete spontaneous abortion was 10.3 ng/ml, while in the control group the mean is 2.8 ng/ml, with P value, 0.001, this agree with Yang, Jiexia et al.⁽²⁷⁾ study in which the median of **9** patients of complete spontaneous abortions was significantly lower (0.430 MOM), while the control group median was 1.002 MOM. Regarding missed abortion :The current study conclude that the level of ADAM 12 in missed abortion is less than that found in normal pregnancy, this agree with Yang, Jiexia et al.⁽²⁷⁾studybut in both studies the level of ADAM 12 is not significant from the control.Regarding molar pregnancy: The mean level of ADAM 12 in molar pregnancy in the current study is 6.4 ng/ml which higher than the level in control group with P value <0.001, this agree with Yang, Jiexia et al.⁽²⁷⁾ study MOM 0.037 which studied (**12 patients**) with molar pregnancy.

VI. Conclusion

The level of the maternal serum ADAM- 12 in early pregnancy considered as indicator of early adverse pregnancy outcome.

References

- [1]. T.W. Sadler; Montana county. Langman's, Medical embryology, 12th edition, 2012, chapter 8, p. 96.
- [2]. Rachel Benson Gold. The Implications of Defining When a Woman Is Pregnant, The Guttmacher Report on Public Policy, May 2005, p.8.
- [3]. Elizabeth Leis-Newman Miscarriage and loss, Losing a pregnancy can affect a woman — and her family — for years, research finds. June 2012, Vol 43, No. 6, page 56
- [4]. Lennart Nilsson, A Child is Born 91 (1990): at eight weeks, "the danger of a miscarriage ... diminishes sharply." "Women's Health Information", Hearststone Communications Limited: "The risk of miscarriage decreases dramatically after the 8th week as the weeks go by." Retrieved 2007-04-22.
- [5]. NHS. The Pregnancy Book, 2009, chapter 2, p.19.
- [6]. D.Keith Edmonds, Philip Savage and Michael Seckl. Gestational Trophoblast Tumors, Dewhurst's Textbook of Obstetrics and Gynecology, eighth edition. Chapter 8; pp. 66-68.
- [7]. Yagami-Hiromasa, T., Sato, T., Kurisaki, T., Kamijo, K., Nabeshima, Y. & Fujisawa-Sehara, A. A metalloprotease-disintegrin participating in myoblast fusion. Nature (London) (1995) 377, pp. 652–656.
- [8]. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387–2392.
- [9]. Prasanna B, Jhansi CB, Swathi K, ShaikMV .a study on risk factors and clinical presentation of ectopic pregnancy in women attending a tertiary centre . IAIM, 2016, 3 (1): 90–96 .
- [10]. J .Pollheimer , V . fock , M .knofler. The ADAM metalloproteinases – Noval regulators of trophoblast invasion .trophoblast research , 2014 Vol. 28 , 557–563 .
- [11]. Darren F. Seals and Sara A. Courtneidge. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Van Andel Research Institute, Grand Rapids, Michigan 49503, USA; 2016; 8.
- [12]. Zengdun Shi, Wenzhong Xu, Frosty Loechel, Ulla M. Wewer, and Liam J. Murphy. ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3. March 15, 2000, and in revised form, April 12, 2000 Published, JBC Papers in Press, April 14, 2000.
- [13]. Iles RK, Wathen NC, Sharma KB, Campbell J, Grudzinskas JG, Chard T. 1994. Pregnancy-associated plasma protein A levels in maternal serum, extraembryonic coelomic and amniotic fluids in the first trimester. Placenta 15: 693–699.
- [14]. Ray BK, Dhar S, Shakya A, Ray A. Z-DNA-forming silencer in the first exon regulates human ADAM-12 gene expression. Proc Natl Acad Sci U S A 2011; 108: 103–108.
- [15]. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA (2004) ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 279: 51323–51330.
- [16]. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM (1995). "Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster". Genetics. 139 (3): 1347–58.
- [17]. Jiyoung Kim, 1 Sung Goo Kang, 2 Jong Il Kim, 3 Joo Hyun Park, 4 Sei Kwang Kim, 4 Dong Jae Cho, 4 and Haekwon Kim. Implication of ADAM-8, -9, -10, -12, -15, -17, and ADAMTS-1 in Implantational Remodeling of a Mouse Uterus. Yonsei Medical Journal Vol. 47, No. 4, pp. 558–567, 2006.
- [18]. Harris LK. Review: Trophoblast-vascular cell interactions in early pregnancy: how to remodel a vessel. Placenta 2010; 31(suppl):S93–98.
- [19]. Suzuki, A., Kadota, N., Hara, T., Nakagami Y., Izumi, T., Takenawa T., Sabe H., and Endo, T. 2000. Meltrin γ cytoplasmic domain interacts with SH3 domains of Src and Grb2 and is phosphorylated by v-Src. Oncogene 19: 5842–5850.
- [20]. Galliano MF, et al. (2000) Binding of ADAM12, a marker of skeletal muscle regeneration, to the muscle-specific actin-binding protein, α -actinin-2, is required for myoblast fusion. J Biol Chem 275: 13933–13939.
- [21]. Laigaard J, Sørensen T, Frølich C, Pedersen BN, Christiansen M, et al (2003) ADAM12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn 23(13): p. 1086–91.
- [22]. Darren F . Seals and Sara A . The ADAMs family of metalloproteases: multidomain proteins with multiple functions . Genes and development . 2016 , 17 : 7–30 .
- [23]. Spencer K, Cowans NJ (2007) ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy. J Matern Fetal Neonatal Med 20(9): p. 645–50.
- [24]. Kang, T., Zhao, Y.G., Pei, D., Sucic, J.F., and Sang, Q.X. 2002. Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites. J. Biol. Chem. 277: 25583–25591.
- [25]. N. J. Cowans 1 , A. Stamatopoulou 1 , S. Jaakohuhta 2 and K. Spencer ADAM-12 stability in first trimester maternal serum. Prenatal Diagnosis 2010; 30: 555–560.
- [26]. Sahraravand M, Jarvela IY, Laitinen P, Tekay AH, Ryyanen M The secretion of PAPP-A, ADAM12, and PP13 correlates with the size of the placenta for the first month of pregnancy. Placenta 32: (2011); pp. 999–1003.
- [27]. Yang J, Wu J, Guo F, Wang D, Chen K, Li J, Du L, Yin A. Maternal serum disintegrin and metalloprotease protein-12 in early pregnancy as a potential marker of adverse pregnancy outcomes. PLoS One. 2014; 9(5): e97284.
- [28]. Rausch ME, Beer L, Sammel MD, Takacs P, Chung, Shaunik A, Speicher D, Barnhart KT. A disintegrin and metalloprotease protein-12 as a novel marker for the diagnosis of ectopic pregnancy. Fertil Steril. 2011; 95(4): 1373–8.
- [29]. Horne AW, Brown Jk, Tong S and Kaitu-Lino T 2014 . evaluation of ADAM- 12 as a diagnostic biomarker of ectopic pregnancy in women with a pregnancy of unknown location . PLoS One , vol 7 , No 8 : e 41442.

*Wasanwajdi. "MaternalSeruma Disintegrin andMetalloprotease Protein-12 (ADAM 12) In First Trimester as a Marker of EarlyAdverse Pregnancy Outcomes." IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) 16.10 (2017): 85-89